The decreased expression of PCK2 may promote EMT by activating cytokines, a series of signaling pathways and altering immune infiltration, and ultimately lead to tumor immune evasion, low survival rate and increased invasivity in patients with liver cancer. This evidence concerns the gene PCK2 and liver cancer.